But IV nutrition therapy has also become popular among the wellness crowd in recent years, thanks to potential perks such as fighting fatigue, boosting immunity, and easing stress. IV nutrition ...

The federal government will spend $20 million to expand the only local manufacturing facility of IV fluids. Production of the medicine is expected to jump from 60 million units a year to 80 ...

Making matters worse, it was reported that soon-to-be free agent linebacker Ernest Jones IV had offseason surgery to clean up his knee, and a new deal between him and the team was yet to be announced.

A low-dose (40 mg) modified formulation of minocycline hydrochloride (DFD-29) was better tolerated and more effective than doxycycline and placebo in patients with moderate to severe ...

Washington, DC: The Executive Board of the International Monetary Fund (IMF) concluded the Article IV consultation [1] with Liechtenstein on March 21, 2025. After exhibiting significant volatility in ...

Candel Therapeutics announced final survival data from a phase 2a clinical trial of CAN-2409 in patients with stage III/IV NSCLC, inadequately responding to ICI treatment. Savara Inc. nnounced ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...

In an announcement, CMS cites the example of Atgam, an IV infusion that is used to treat a rare blood condition known as ...

Minocycline is a tetracycline analogue that has been used in clinical trials for stroke, multiple sclerosis and several neurodegenerative conditions.

Historically, oral antibiotics, particularly minocycline, have been the mainstay of treatment due to their dual antimicrobial and anti-inflammatory properties. However, concerns over long-term ...

Glaucoma, a leading cause of irreversible blindness, represents a significant challenge in ophthalmology. This review examines recent advancements in glaucoma treatment, focusing on innovative ...